A multicenter observational case–control study that included 80 patients with T2DM and Graves’ disease who were administered an oral hypoglycemic agent, including DPP-4 inhibitors, showed that there is a suggestive association between DPP-4 inhibitors and Graves’ disease exacerbation [109]. The gene discussed is DPP4; the disease is Graves disease.